Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts

Tempus AI, Inc. (NASDAQ:TEM) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $58.55.

Several analysts have recently commented on the stock. TD Cowen reissued a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, Bank of America raised their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th.

Insider Transactions at Tempus AI

In related news, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at $10,431,543.15. This trade represents a 17.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total transaction of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. The trade was a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,401,779 shares of company stock valued at $115,707,361 over the last three months.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Operose Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at $25,000. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter valued at $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC increased its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

NASDAQ TEM opened at $81.95 on Wednesday. Tempus AI has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a 50 day moving average of $47.46 and a 200-day moving average of $50.72.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.